| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Testosterone | 80 | 2026 | 604 | 16.700 |
Why?
|
| Hypogonadism | 54 | 2026 | 323 | 13.860 |
Why?
|
| Erectile Dysfunction | 39 | 2026 | 197 | 12.540 |
Why?
|
| Hormone Replacement Therapy | 40 | 2026 | 215 | 10.360 |
Why?
|
| Prostatic Neoplasms | 32 | 2025 | 1419 | 5.730 |
Why?
|
| Androgens | 17 | 2025 | 272 | 4.460 |
Why?
|
| Penile Prosthesis | 11 | 2024 | 40 | 3.980 |
Why?
|
| Penile Implantation | 8 | 2024 | 25 | 3.580 |
Why?
|
| Cardiovascular Diseases | 22 | 2025 | 2098 | 2.560 |
Why?
|
| Prostatectomy | 18 | 2022 | 313 | 2.280 |
Why?
|
| Penile Induration | 5 | 2024 | 38 | 2.230 |
Why?
|
| Prostate-Specific Antigen | 12 | 2025 | 236 | 2.210 |
Why?
|
| Penile Erection | 15 | 2023 | 80 | 2.150 |
Why?
|
| Male | 135 | 2026 | 65425 | 2.120 |
Why?
|
| Urology | 5 | 2025 | 84 | 2.100 |
Why?
|
| Patient Satisfaction | 9 | 2025 | 460 | 1.500 |
Why?
|
| Libido | 4 | 2022 | 34 | 1.490 |
Why?
|
| Stem Cell Transplantation | 3 | 2024 | 235 | 1.490 |
Why?
|
| Humans | 139 | 2026 | 132041 | 1.450 |
Why?
|
| Penis | 9 | 2025 | 97 | 1.290 |
Why?
|
| Depression | 5 | 2026 | 1350 | 1.260 |
Why?
|
| Sexual Behavior | 8 | 2024 | 244 | 1.110 |
Why?
|
| Sexual Dysfunction, Physiological | 6 | 2025 | 84 | 1.090 |
Why?
|
| Sexual Health | 2 | 2025 | 19 | 1.050 |
Why?
|
| Urologists | 1 | 2025 | 11 | 0.910 |
Why?
|
| Holistic Health | 1 | 2025 | 12 | 0.890 |
Why?
|
| Middle Aged | 46 | 2025 | 28946 | 0.880 |
Why?
|
| Finasteride | 2 | 2022 | 16 | 0.880 |
Why?
|
| Microbial Collagenase | 1 | 2024 | 10 | 0.870 |
Why?
|
| Commerce | 1 | 2025 | 57 | 0.860 |
Why?
|
| Platelet-Rich Plasma | 1 | 2024 | 23 | 0.860 |
Why?
|
| Watchful Waiting | 1 | 2025 | 73 | 0.850 |
Why?
|
| Reproductive Health | 2 | 2024 | 48 | 0.850 |
Why?
|
| Androgen Antagonists | 2 | 2024 | 114 | 0.830 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2023 | 20 | 0.820 |
Why?
|
| Career Choice | 1 | 2025 | 163 | 0.800 |
Why?
|
| Aged | 39 | 2025 | 21288 | 0.800 |
Why?
|
| Health Care Costs | 3 | 2018 | 401 | 0.790 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2025 | 142 | 0.790 |
Why?
|
| Prosthesis Design | 4 | 2024 | 614 | 0.750 |
Why?
|
| Urinary Sphincter, Artificial | 1 | 2021 | 6 | 0.720 |
Why?
|
| Urinary Incontinence, Stress | 1 | 2021 | 32 | 0.710 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2021 | 14 | 0.700 |
Why?
|
| Adult | 36 | 2025 | 31747 | 0.680 |
Why?
|
| Fellowships and Scholarships | 1 | 2024 | 325 | 0.680 |
Why?
|
| Cystic Fibrosis | 1 | 2024 | 267 | 0.680 |
Why?
|
| Treatment Outcome | 24 | 2026 | 13025 | 0.650 |
Why?
|
| Polycythemia | 1 | 2020 | 45 | 0.640 |
Why?
|
| Eunuchism | 2 | 2022 | 7 | 0.630 |
Why?
|
| Telemedicine | 2 | 2024 | 522 | 0.630 |
Why?
|
| Surveys and Questionnaires | 12 | 2026 | 4071 | 0.620 |
Why?
|
| Retrospective Studies | 21 | 2025 | 17748 | 0.590 |
Why?
|
| Prostate | 4 | 2023 | 415 | 0.590 |
Why?
|
| Curriculum | 1 | 2024 | 786 | 0.590 |
Why?
|
| Fertility | 2 | 2018 | 266 | 0.580 |
Why?
|
| Botulinum Toxins, Type A | 3 | 2005 | 126 | 0.580 |
Why?
|
| Clomiphene | 1 | 2018 | 16 | 0.570 |
Why?
|
| North America | 7 | 2024 | 260 | 0.570 |
Why?
|
| Spinal Cord Injuries | 3 | 2007 | 279 | 0.560 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2017 | 51 | 0.530 |
Why?
|
| Aromatase Inhibitors | 1 | 2017 | 78 | 0.520 |
Why?
|
| Societies, Medical | 5 | 2024 | 797 | 0.500 |
Why?
|
| Quality of Life | 8 | 2025 | 2118 | 0.500 |
Why?
|
| Varicocele | 4 | 2010 | 61 | 0.490 |
Why?
|
| Prospective Studies | 12 | 2025 | 6539 | 0.470 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2017 | 256 | 0.470 |
Why?
|
| Abdominal Wall | 1 | 2015 | 25 | 0.460 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2024 | 1249 | 0.440 |
Why?
|
| Postoperative Complications | 7 | 2024 | 3133 | 0.440 |
Why?
|
| Mass Screening | 2 | 2024 | 825 | 0.430 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2015 | 81 | 0.430 |
Why?
|
| Drug Implants | 5 | 2015 | 43 | 0.430 |
Why?
|
| Medication Adherence | 1 | 2018 | 333 | 0.420 |
Why?
|
| Men's Health | 3 | 2024 | 22 | 0.420 |
Why?
|
| Prostatic Hyperplasia | 3 | 2023 | 119 | 0.410 |
Why?
|
| Urinary Bladder | 2 | 2005 | 250 | 0.400 |
Why?
|
| Pandemics | 1 | 2021 | 1169 | 0.400 |
Why?
|
| Extracorporeal Shockwave Therapy | 2 | 2024 | 10 | 0.380 |
Why?
|
| Osteoporotic Fractures | 1 | 2012 | 30 | 0.370 |
Why?
|
| Carcinoma | 1 | 2015 | 284 | 0.370 |
Why?
|
| Comorbidity | 6 | 2018 | 1609 | 0.370 |
Why?
|
| United States | 17 | 2023 | 11846 | 0.370 |
Why?
|
| Registries | 9 | 2018 | 1601 | 0.360 |
Why?
|
| Urologic Diseases | 2 | 2023 | 43 | 0.360 |
Why?
|
| Klinefelter Syndrome | 1 | 2011 | 20 | 0.350 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 506 | 0.350 |
Why?
|
| Deficiency Diseases | 1 | 2011 | 9 | 0.340 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2011 | 54 | 0.340 |
Why?
|
| Heart Diseases | 1 | 2016 | 505 | 0.340 |
Why?
|
| Coitus | 2 | 2025 | 22 | 0.340 |
Why?
|
| Patient Compliance | 2 | 2011 | 469 | 0.330 |
Why?
|
| Aging | 2 | 2016 | 1270 | 0.330 |
Why?
|
| Impotence, Vasculogenic | 1 | 2010 | 7 | 0.330 |
Why?
|
| Public Health | 1 | 2012 | 277 | 0.320 |
Why?
|
| Nitric Oxide | 1 | 2013 | 469 | 0.320 |
Why?
|
| Risk Factors | 12 | 2021 | 11020 | 0.310 |
Why?
|
| Aged, 80 and over | 12 | 2023 | 6930 | 0.310 |
Why?
|
| Prevalence | 4 | 2018 | 2705 | 0.300 |
Why?
|
| Medicare | 5 | 2023 | 439 | 0.300 |
Why?
|
| Urologic Surgical Procedures, Male | 3 | 2019 | 34 | 0.300 |
Why?
|
| Cardiovascular System | 3 | 2021 | 105 | 0.290 |
Why?
|
| Female | 14 | 2026 | 71380 | 0.270 |
Why?
|
| Administration, Oral | 3 | 2025 | 710 | 0.270 |
Why?
|
| Rats, Sprague-Dawley | 6 | 2015 | 1147 | 0.270 |
Why?
|
| Disease Progression | 3 | 2025 | 2229 | 0.270 |
Why?
|
| Gels | 4 | 2023 | 70 | 0.260 |
Why?
|
| Operative Time | 3 | 2018 | 205 | 0.260 |
Why?
|
| Animals | 12 | 2025 | 34262 | 0.260 |
Why?
|
| Receptors, Epoprostenol | 1 | 2007 | 6 | 0.260 |
Why?
|
| Cell Proliferation | 1 | 2014 | 2477 | 0.260 |
Why?
|
| Databases, Factual | 3 | 2023 | 1228 | 0.260 |
Why?
|
| Linear Models | 3 | 2013 | 696 | 0.250 |
Why?
|
| Urinary Bladder, Overactive | 1 | 2007 | 30 | 0.250 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2007 | 42 | 0.250 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2022 | 744 | 0.250 |
Why?
|
| Behavior Therapy | 2 | 2023 | 272 | 0.240 |
Why?
|
| Incidence | 5 | 2021 | 3358 | 0.240 |
Why?
|
| Urinary Incontinence | 1 | 2006 | 73 | 0.230 |
Why?
|
| Neurotoxins | 1 | 2005 | 45 | 0.230 |
Why?
|
| Sensation | 1 | 2005 | 49 | 0.230 |
Why?
|
| Muscle Strength | 1 | 2025 | 82 | 0.220 |
Why?
|
| Biomarkers | 3 | 2025 | 3422 | 0.220 |
Why?
|
| Rats | 6 | 2020 | 3458 | 0.220 |
Why?
|
| Mice, Nude | 2 | 2017 | 713 | 0.220 |
Why?
|
| Liver Function Tests | 1 | 2025 | 97 | 0.220 |
Why?
|
| Sexology | 1 | 2024 | 4 | 0.220 |
Why?
|
| Spermatogenesis | 2 | 2018 | 171 | 0.220 |
Why?
|
| Injections, Intralesional | 1 | 2024 | 46 | 0.220 |
Why?
|
| Urethral Stricture | 1 | 2004 | 13 | 0.220 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2025 | 152 | 0.220 |
Why?
|
| Estradiol | 3 | 2021 | 482 | 0.220 |
Why?
|
| Semen Analysis | 1 | 2024 | 37 | 0.210 |
Why?
|
| Cosmetic Techniques | 1 | 2024 | 11 | 0.210 |
Why?
|
| Cell Line, Tumor | 3 | 2017 | 3703 | 0.210 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2024 | 48 | 0.210 |
Why?
|
| Cholesterol, HDL | 1 | 2025 | 394 | 0.200 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2023 | 1420 | 0.200 |
Why?
|
| Adenosine Triphosphate | 1 | 2004 | 265 | 0.200 |
Why?
|
| Urinary Retention | 1 | 2023 | 18 | 0.200 |
Why?
|
| Alprostadil | 2 | 2016 | 22 | 0.200 |
Why?
|
| Neuromuscular Agents | 1 | 2004 | 64 | 0.200 |
Why?
|
| Neurocognitive Disorders | 1 | 2024 | 74 | 0.200 |
Why?
|
| Time Factors | 4 | 2024 | 6283 | 0.200 |
Why?
|
| Bayes Theorem | 1 | 2024 | 307 | 0.200 |
Why?
|
| Health Expenditures | 2 | 2016 | 134 | 0.190 |
Why?
|
| Patient Preference | 1 | 2025 | 147 | 0.190 |
Why?
|
| Blood Pressure | 2 | 2021 | 1347 | 0.190 |
Why?
|
| Drug Administration Schedule | 3 | 2013 | 739 | 0.190 |
Why?
|
| Triglycerides | 1 | 2025 | 605 | 0.190 |
Why?
|
| Cholesterol | 1 | 2025 | 541 | 0.190 |
Why?
|
| Receptors, Androgen | 3 | 2014 | 419 | 0.190 |
Why?
|
| Priapism | 1 | 2022 | 11 | 0.190 |
Why?
|
| Insurance Coverage | 1 | 2023 | 117 | 0.180 |
Why?
|
| Sildenafil Citrate | 2 | 2013 | 57 | 0.180 |
Why?
|
| Young Adult | 9 | 2024 | 10128 | 0.180 |
Why?
|
| Clinical Trials as Topic | 2 | 2025 | 1140 | 0.180 |
Why?
|
| Life Style | 1 | 2025 | 447 | 0.180 |
Why?
|
| Patient Education as Topic | 1 | 2025 | 466 | 0.170 |
Why?
|
| Biopsy | 1 | 2025 | 1254 | 0.170 |
Why?
|
| Longitudinal Studies | 1 | 2025 | 1525 | 0.170 |
Why?
|
| Orchiectomy | 2 | 2017 | 52 | 0.160 |
Why?
|
| Traction | 1 | 2019 | 10 | 0.150 |
Why?
|
| Azoospermia | 2 | 2010 | 48 | 0.150 |
Why?
|
| Lung Transplantation | 1 | 2024 | 357 | 0.150 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 2 | 2016 | 34 | 0.150 |
Why?
|
| Placenta | 1 | 2023 | 526 | 0.150 |
Why?
|
| Muscle, Skeletal | 1 | 2025 | 1002 | 0.150 |
Why?
|
| Regenerative Medicine | 1 | 2019 | 39 | 0.150 |
Why?
|
| Neoplasm Grading | 2 | 2021 | 277 | 0.150 |
Why?
|
| Single-Blind Method | 1 | 2019 | 242 | 0.150 |
Why?
|
| Dementia | 1 | 2024 | 436 | 0.140 |
Why?
|
| Insurance, Health | 1 | 2019 | 140 | 0.140 |
Why?
|
| Infertility, Male | 3 | 2024 | 297 | 0.140 |
Why?
|
| Reoperation | 1 | 2021 | 846 | 0.140 |
Why?
|
| Lipids | 3 | 2023 | 566 | 0.140 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2018 | 64 | 0.140 |
Why?
|
| Anemia, Sickle Cell | 1 | 2022 | 325 | 0.140 |
Why?
|
| Chorionic Gonadotropin | 1 | 2018 | 79 | 0.140 |
Why?
|
| Estrogen Antagonists | 1 | 2018 | 92 | 0.140 |
Why?
|
| Hematocrit | 2 | 2021 | 108 | 0.140 |
Why?
|
| Organ Transplantation | 1 | 2020 | 173 | 0.140 |
Why?
|
| Double-Blind Method | 3 | 2023 | 1637 | 0.140 |
Why?
|
| Sex Hormone-Binding Globulin | 3 | 2014 | 50 | 0.140 |
Why?
|
| Caffeine | 1 | 2018 | 67 | 0.140 |
Why?
|
| Exercise | 1 | 2023 | 867 | 0.130 |
Why?
|
| Recovery of Function | 4 | 2022 | 452 | 0.130 |
Why?
|
| Liver | 1 | 2025 | 1805 | 0.130 |
Why?
|
| Pilot Projects | 2 | 2024 | 1474 | 0.130 |
Why?
|
| Biomarkers, Tumor | 2 | 2015 | 1621 | 0.130 |
Why?
|
| Gene Expression | 1 | 2021 | 1508 | 0.130 |
Why?
|
| Tumor Burden | 1 | 2017 | 241 | 0.130 |
Why?
|
| Diabetes Complications | 2 | 2015 | 199 | 0.120 |
Why?
|
| Dosage Forms | 1 | 2016 | 9 | 0.120 |
Why?
|
| Administration, Cutaneous | 2 | 2013 | 68 | 0.120 |
Why?
|
| Thrombosis | 1 | 2021 | 497 | 0.120 |
Why?
|
| Fasciotomy | 1 | 2015 | 26 | 0.120 |
Why?
|
| Cohort Studies | 4 | 2020 | 5124 | 0.120 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 5287 | 0.120 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 315 | 0.120 |
Why?
|
| Age Distribution | 1 | 2016 | 429 | 0.110 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 155 | 0.110 |
Why?
|
| Endocrinology | 1 | 2017 | 128 | 0.110 |
Why?
|
| Heterografts | 1 | 2015 | 195 | 0.110 |
Why?
|
| Vulvodynia | 1 | 2014 | 4 | 0.110 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2014 | 18 | 0.110 |
Why?
|
| Luteinizing Hormone | 4 | 2015 | 133 | 0.110 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2015 | 40 | 0.110 |
Why?
|
| History, 21st Century | 1 | 2015 | 258 | 0.110 |
Why?
|
| Heart Rate | 1 | 2017 | 580 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 2 | 2015 | 545 | 0.110 |
Why?
|
| Reproduction | 1 | 2016 | 217 | 0.110 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 1000 | 0.110 |
Why?
|
| Nanostructures | 1 | 2014 | 64 | 0.110 |
Why?
|
| History, 20th Century | 1 | 2015 | 365 | 0.100 |
Why?
|
| Case-Control Studies | 1 | 2021 | 3457 | 0.100 |
Why?
|
| Osteoporosis | 1 | 2015 | 134 | 0.100 |
Why?
|
| Androgen-Insensitivity Syndrome | 1 | 2013 | 26 | 0.100 |
Why?
|
| Postoperative Period | 3 | 2022 | 335 | 0.100 |
Why?
|
| Nitric Oxide Synthase | 2 | 2016 | 168 | 0.100 |
Why?
|
| Streptozocin | 1 | 2013 | 26 | 0.100 |
Why?
|
| Microspheres | 1 | 2013 | 68 | 0.100 |
Why?
|
| Bone Density | 1 | 2016 | 362 | 0.100 |
Why?
|
| Disease Management | 1 | 2017 | 561 | 0.100 |
Why?
|
| Body Composition | 1 | 2016 | 550 | 0.100 |
Why?
|
| Sulfones | 1 | 2013 | 73 | 0.100 |
Why?
|
| Education, Medical, Continuing | 1 | 2014 | 133 | 0.100 |
Why?
|
| Purines | 1 | 2013 | 115 | 0.100 |
Why?
|
| Health Surveys | 2 | 2011 | 263 | 0.100 |
Why?
|
| Adolescent | 5 | 2022 | 21018 | 0.090 |
Why?
|
| Decision Making | 1 | 2018 | 689 | 0.090 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2013 | 187 | 0.090 |
Why?
|
| Pregnancy | 2 | 2023 | 7588 | 0.090 |
Why?
|
| Risk Assessment | 2 | 2021 | 3718 | 0.090 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2013 | 147 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2013 | 431 | 0.090 |
Why?
|
| Tadalafil | 1 | 2011 | 4 | 0.090 |
Why?
|
| Hemoglobins | 1 | 2013 | 288 | 0.090 |
Why?
|
| Piperazines | 1 | 2013 | 273 | 0.090 |
Why?
|
| Polymorphism, Genetic | 1 | 2014 | 793 | 0.090 |
Why?
|
| Analysis of Variance | 1 | 2013 | 956 | 0.080 |
Why?
|
| Prosthesis-Related Infections | 1 | 2013 | 194 | 0.080 |
Why?
|
| Muscle Contraction | 2 | 2016 | 154 | 0.080 |
Why?
|
| Insulin Resistance | 1 | 2016 | 683 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 778 | 0.080 |
Why?
|
| Sexual Partners | 1 | 2011 | 82 | 0.080 |
Why?
|
| Logistic Models | 2 | 2018 | 1841 | 0.080 |
Why?
|
| Risk | 1 | 2012 | 739 | 0.080 |
Why?
|
| Chronic Disease | 2 | 2005 | 1240 | 0.080 |
Why?
|
| Body Mass Index | 2 | 2018 | 1697 | 0.080 |
Why?
|
| Cause of Death | 1 | 2012 | 511 | 0.080 |
Why?
|
| Health Status Indicators | 1 | 2010 | 124 | 0.080 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 1173 | 0.080 |
Why?
|
| Organ Size | 1 | 2010 | 438 | 0.080 |
Why?
|
| Program Development | 1 | 2010 | 181 | 0.080 |
Why?
|
| Pregnancy Outcome | 1 | 2012 | 630 | 0.080 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2009 | 6 | 0.070 |
Why?
|
| Mice | 2 | 2017 | 18394 | 0.070 |
Why?
|
| Patient Safety | 1 | 2014 | 447 | 0.070 |
Why?
|
| Vasodilator Agents | 1 | 2010 | 205 | 0.070 |
Why?
|
| Drug Monitoring | 1 | 2012 | 288 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2012 | 1522 | 0.070 |
Why?
|
| Age Factors | 4 | 2019 | 2868 | 0.070 |
Why?
|
| Evidence-Based Medicine | 3 | 2017 | 645 | 0.070 |
Why?
|
| Veins | 1 | 2009 | 99 | 0.070 |
Why?
|
| Health Status | 1 | 2010 | 389 | 0.070 |
Why?
|
| Preoperative Care | 1 | 2010 | 358 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 3851 | 0.070 |
Why?
|
| Laparoscopy | 2 | 2013 | 555 | 0.070 |
Why?
|
| Odds Ratio | 1 | 2010 | 1237 | 0.060 |
Why?
|
| Analgesics, Opioid | 1 | 2012 | 471 | 0.060 |
Why?
|
| Embolization, Therapeutic | 1 | 2009 | 225 | 0.060 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 4691 | 0.060 |
Why?
|
| Sex Factors | 1 | 2010 | 1352 | 0.060 |
Why?
|
| International Cooperation | 2 | 2017 | 162 | 0.060 |
Why?
|
| Minimal Clinically Important Difference | 1 | 2026 | 10 | 0.060 |
Why?
|
| Hand Strength | 1 | 2025 | 58 | 0.060 |
Why?
|
| Masturbation | 1 | 2025 | 2 | 0.060 |
Why?
|
| Constriction | 1 | 2025 | 47 | 0.060 |
Why?
|
| Sarcopenia | 1 | 2025 | 56 | 0.060 |
Why?
|
| Recurrence | 2 | 2009 | 1484 | 0.050 |
Why?
|
| Vascular Surgical Procedures | 1 | 2009 | 540 | 0.050 |
Why?
|
| Retreatment | 1 | 2004 | 87 | 0.050 |
Why?
|
| Follicle Stimulating Hormone | 2 | 2015 | 188 | 0.050 |
Why?
|
| Urothelium | 1 | 2004 | 61 | 0.050 |
Why?
|
| Random Allocation | 1 | 2025 | 423 | 0.050 |
Why?
|
| Transdermal Patch | 1 | 2023 | 8 | 0.050 |
Why?
|
| Phenylephrine | 1 | 2022 | 37 | 0.050 |
Why?
|
| Testosterone Congeners | 1 | 2022 | 15 | 0.050 |
Why?
|
| Equivalence Trials as Topic | 1 | 2021 | 22 | 0.050 |
Why?
|
| Isotretinoin | 1 | 2022 | 19 | 0.050 |
Why?
|
| Prosthesis Failure | 1 | 2022 | 149 | 0.040 |
Why?
|
| Monitoring, Ambulatory | 1 | 2021 | 57 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2021 | 300 | 0.040 |
Why?
|
| HIV Infections | 1 | 2013 | 2040 | 0.040 |
Why?
|
| SEER Program | 1 | 2021 | 210 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2022 | 337 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 2 | 2016 | 1306 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2018 | 95 | 0.030 |
Why?
|
| Critical Pathways | 1 | 2018 | 74 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2018 | 157 | 0.030 |
Why?
|
| Polypharmacy | 1 | 2017 | 36 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2021 | 1333 | 0.030 |
Why?
|
| Survival Rate | 1 | 2022 | 2154 | 0.030 |
Why?
|
| Premature Ejaculation | 1 | 2016 | 4 | 0.030 |
Why?
|
| Child | 3 | 2022 | 26361 | 0.030 |
Why?
|
| Nutrition Surveys | 1 | 2018 | 327 | 0.030 |
Why?
|
| Muscle, Smooth | 1 | 2016 | 128 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2023 | 1002 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 1411 | 0.030 |
Why?
|
| Patient Participation | 1 | 2018 | 245 | 0.030 |
Why?
|
| Stroke | 1 | 2023 | 1051 | 0.030 |
Why?
|
| 2-Hydroxypropyl-beta-cyclodextrin | 1 | 2014 | 6 | 0.030 |
Why?
|
| beta-Cyclodextrins | 1 | 2014 | 12 | 0.030 |
Why?
|
| Luminescent Measurements | 1 | 2014 | 56 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 2017 | 471 | 0.030 |
Why?
|
| Trinucleotide Repeats | 1 | 2014 | 106 | 0.030 |
Why?
|
| Patient Admission | 1 | 2015 | 186 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2014 | 215 | 0.020 |
Why?
|
| Kinetics | 1 | 2014 | 1093 | 0.020 |
Why?
|
| Canada | 1 | 2013 | 329 | 0.020 |
Why?
|
| Robotics | 1 | 2013 | 108 | 0.020 |
Why?
|
| Body Weights and Measures | 1 | 2011 | 37 | 0.020 |
Why?
|
| Reference Values | 1 | 2012 | 692 | 0.020 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2011 | 41 | 0.020 |
Why?
|
| Personal Satisfaction | 1 | 2011 | 102 | 0.020 |
Why?
|
| Patient Selection | 1 | 2014 | 726 | 0.020 |
Why?
|
| Affect | 1 | 2011 | 170 | 0.020 |
Why?
|
| Ligation | 1 | 2009 | 137 | 0.020 |
Why?
|
| Alleles | 1 | 2014 | 1708 | 0.020 |
Why?
|
| Hospital Costs | 1 | 2009 | 180 | 0.020 |
Why?
|
| Genotype | 1 | 2014 | 2655 | 0.020 |
Why?
|
| Algorithms | 1 | 2015 | 1690 | 0.020 |
Why?
|
| Equipment Design | 1 | 2009 | 557 | 0.020 |
Why?
|
| Radiography | 1 | 2009 | 763 | 0.020 |
Why?
|
| Metabolic Syndrome | 1 | 2011 | 366 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2011 | 1105 | 0.020 |
Why?
|
| Obesity | 1 | 2011 | 2394 | 0.010 |
Why?
|